A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

Phase 1

• Conditions: Nasopharyngeal Neoplasms

• Registration Number: NCT02980315
• Lead Sponsor: The Second Hospital of Nanjing Medical University

Brief Summary

The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.

Detailed Description

Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.

Study Timeline

• Status Verified: 2016-11
• Study Start: 2016-11
• Study First Submitted: 2016-11-30
• Study First Submitted QC: 2016-11-30
• Last Update Submitted: 2016-11-30
• Study First Posted: 2016-12-02
• Last Update Posted: 2016-12-02
• Primary Completion: 2017-12
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Clinical diagnosis of nasopharyngeal carcinoma

Exclusion Criteria

• •pregnant woman

  • severe autoimmune diseases
  • serious infection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
all cause mortality	one year

Trial Locations

Locations (1)

SecondNanjingMU; 🇨🇳 Nanjing, Jiangsu, China